Skip to main content
. Author manuscript; available in PMC: 2022 Mar 6.
Published in final edited form as: Cell Rep. 2022 Feb 15;38(7):110358. doi: 10.1016/j.celrep.2022.110358

Figure 3. Iron chelation therapy reduces α-syn-PFF-mediated dopaminergic cell death and behavioral deficits.

Figure 3.

(A) DFP treatment partially rescues α-syn-PFF-induced TH- and Nissl-positive neuronal loss. n = 7 biological replicates per group. Scale bar, 400 μm.

(B) DFP treatment partially rescues α-syn-PFF-induced decrease in neuronal TH and DAT protein levels by western analysis. n = 3 biological replicates per group.

(C) DFP treatment reduces deficit in pole test performance of α-syn-PFF-injected mice.

(D and E) DFP treatment improves grip strength in α-syn-PFF-injected mice. Total grip strength shown in (D). Forelimb strength only shown in (E). n = 9–11 biological replicates per group.

Data indicate mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, by two-way ANOVA (A–E) with Tukey’s HSD post hoc test.